Dissecting the Molecular & Cellular Pathophysiology of Sarcopenic Obesity

Status Recruiting

Clinical Trial Summary

Ageing is characterised by a change in body composition with a parallel decrease in muscle mass and an increase and central redistribution of fat. When drastically exacerbated, these two processes culminate in a condition known as sarcopenic obesity (SO). SO is characterised by the coexistence of obesity and sarcopenia (i.e. reduced muscle mass and function) and is a growing public health problem in the elderly. The health risks of obesity and sarcopenia act synergistically, maximising the risk of disability of OS. The molecular mechanisms underlying OS are largely unknown. Increased fat mass induces chronic systemic inflammation and alters the profiles of adipokines and hormones, promoting the development of sarcopenia. On the other hand, the reduction in muscle tissue (SM) typical of sarcopenia is characterised by an alteration in the metabolic properties of skeletal muscle with an increase in insulin resistance and a reduction in energy expenditure that favours the accumulation and dysfunction of adipose tissue (AT). The cellular alterations that would seem to underlie OS are: altered autophagy, cellular senescence, epigenetic and mitochondrial alterations and maladaptive activation of intra- and intercellular inflammatory circuits (e.g. cytokines, extracellular vesicles, dysfunctional circulating leukocytes). However, the interconnections between these mechanisms are still unclear. The impact of OS can be dramatic on the health and quality of life of those affected. Therefore, the identification of early biomarkers that can recognise overweight and obese individuals at risk of developing SO is of paramount importance. This would shed light on the heterogeneity of an otherwise homogeneous clinical condition, opening new horizons towards the conscious design of more personalised therapeutic strategies, allowing a more rational use of the limited resources available for the growing elderly population. The study design designed to achieve this aim is a cross-sectional observational study with an additional multicentre procedure lasting two years.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06320158
Study type	Observational
Source	IRCCS San Raffaele
Contact	Patrizia Rovere Querini, PhD, MD
Phone	+390226436095
Email	rovere.patrizia@hsr.it
Status	Recruiting
Phase
Start date	May 22, 2023
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03119610` - The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity	Phase 1/Phase 2
Recruiting	`NCT03212391` - WAVE Study- Walking and Aging in VErona Study	N/A
Recruiting	`NCT05289219` - Effects of Physical Exercise on Sarcopenia After Bariatric Surgery	N/A
Completed	`NCT05143398` - Nutritional Supplementation in Sarcopenic Obesity	N/A
Completed	`NCT04122638` - Prevalence of Sarcopenia and Sarcopenic Obesity in Older Adults
Recruiting	`NCT05582668` - Sarcopenia After Bariatric Surgery in Older Patients: A Cohort Study
Active, not recruiting	`NCT02379026` - Lifestyle Modifications for the Treatment of Sarcopenic Obesity	N/A
Enrolling by invitation	`NCT05638035` - Effects of Obesity on Rectus Femoris Muscle Thickness, Sarcopenia, Gait and Balance in Women
Recruiting	`NCT05477277` - Adverse Outcomes and Mortality in Liver Transplant	N/A
Not yet recruiting	`NCT04597788` - Efficacy of Protein Supplemented Very Low Calorie Meals on Weight Loss	N/A
Completed	`NCT04771377` - Effect of Protein Supplementation and a Structured Exercise Program on Muscle in Women After Bariatric Surgery.	N/A
Recruiting	`NCT03347773` - Oral Nutritional Supplement Intervention Among Hemodialysis Patients With Sarcopenic Obesity	N/A
Active, not recruiting	`NCT04272073` - A High-PRotein Mediterranean Diet and Resistance Exercise for Cardiac Rehabilitation	N/A
Completed	`NCT03863379` - Sarcopenic Obesity in Neurodisabilities
Recruiting	`NCT04221750` - Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors	Phase 3
Completed	`NCT05918159` - Effects of Sarcopenia on General Health Status in Elderly: a Population-based Study
Completed	`NCT05029713` - Sarcopenic Obesity in Liver Transplanted Patients
Completed	`NCT03370211` - Resistance Training and Sarcopenic Obesity Elderly Women	N/A
Recruiting	`NCT05734755` - Dietary Programme and Exercise Training in Combination or Separately on Managing Sarcopenic Obesity in Older Adults	N/A
Completed	`NCT05938205` - Multicomponent Analysis of phYsical Frailty BiomarkErs: Focus on Mitochondrial Health - MAYBE	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Dissecting the Molecular and Cellular Pathophysiology of Sarcopenic Obesity in the Elderly

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms